Stockscreener 앱 받기
8.76
0.11%
-0.010
시간 외 거래:
8.77
0.010
+0.11%
전일 마감가:
$8.77
열려 있는:
$8.75
하루 거래량:
1.99M
Relative Volume:
1.10
시가총액:
$548.56M
수익:
$91.06M
순이익/손실:
$-503.14M
주가수익비율:
-1.0441
EPS:
-8.39
순현금흐름:
$-424.74M
1주 성능:
-4.16%
1개월 성능:
-4.99%
6개월 성능:
+23.38%
1년 성능:
-15.61%
1일 변동 폭
$8.75
$8.79
1주일 범위
$8.74
$9.17
52주 변동 폭
$4.62
$11.44
Sage Therapeutics Inc Stock (SAGE) Company Profile
명칭
Sage Therapeutics Inc
전화
617-299-8380
주소
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
SAGE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
8.76 | 547.94M | 91.06M | -503.14M | -424.74M | -8.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-11 | 재개 | BofA Securities | Underperform |
| 2024-11-21 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-10-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-07-30 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-07-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-05-29 | 개시 | Citigroup | Sell |
| 2024-05-29 | 개시 | Robert W. Baird | Neutral |
| 2024-04-17 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-12-12 | 개시 | Deutsche Bank | Hold |
| 2023-08-08 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-08-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-08-08 | 다운그레이드 | Needham | Buy → Hold |
| 2023-08-07 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-08-07 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-08-07 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-08-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-03-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-11-01 | 개시 | Loop Capital | Hold |
| 2022-03-31 | 개시 | Berenberg | Hold |
| 2021-11-02 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-06-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-04-07 | 개시 | Piper Sandler | Overweight |
| 2021-02-26 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-02-25 | 재확인 | H.C. Wainwright | Neutral |
| 2021-02-02 | 재개 | Raymond James | Mkt Perform |
| 2021-01-22 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-01-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-04 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-06 | 재확인 | H.C. Wainwright | Neutral |
| 2020-09-11 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-08-10 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-05-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-04-08 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-03-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-28 | 재확인 | H.C. Wainwright | Neutral |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-06 | 재확인 | RBC Capital Mkts | Outperform |
| 2019-12-05 | 재확인 | Guggenheim | Buy |
| 2019-12-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-10-30 | 개시 | H.C. Wainwright | Neutral |
| 2019-05-23 | 개시 | Wedbush | Outperform |
| 2019-04-25 | 개시 | Jefferies | Buy |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-11 | 개시 | Oppenheimer | Outperform |
모두보기
Sage Therapeutics Inc 주식(SAGE)의 최신 뉴스
What drives Sage Therapeutics Inc. stock priceUnbelievable profit margins - Autocar Professional
What analysts say about Sage Therapeutics Inc. stockFree Investment Community - Autocar Professional
Sage Therapeutics Inc. Stock Analysis and ForecastMarket-beating returns - jammulinksnews.com
Is Sage Therapeutics Inc. a good long term investmentFree Daily Trading Room Entry - jammulinksnews.com
Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace
Sage Therapeutics (NASDAQ:SAGE) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Stock Price Crosses Above 50 Day Moving AverageHere's Why - MarketBeat
ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition of Sage Therapeutics, Inc. - 富途牛牛
Status Epilepticus Pipeline 2025: Key Companies, MOA, ROA, - openPR.com
Status Epilepticus Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Marinus Pharmac, Pfizer, UCB Biopharma, Rafa Laboratories, Sage Therapeutics - The Globe and Mail
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc.SAGE - Business Wire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Reach Out - ACCESS Newswire
Sage Therapeutics (NASDAQ:SAGE) Downgraded to Hold Rating by Scotiabank - MarketBeat
SAGE Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Sage Therapeutics, Inc. is Fair to Shareholders - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Connect - ACCESS Newswire
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Rating of "Reduce" from Analysts - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Rating Lowered to “Hold” at Scotiabank - Defense World
Sage Therapeutics Announces Workforce Reductions Following Recent Acquisition Plans - geneonline.com
Postpartum Depression Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research - Barchart.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out - ACCESS Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVEE, SAGE, OLO on Behalf of Shareholders - Morningstar
Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock - Nasdaq
SAGE: Scotiabank Downgrades Sage Therapeutics with Price Target Adjustment | SAGE Stock News - GuruFocus
Scotiabank Downgrades SAGE Therapeutics to Sector Perform From Sector Outperform, Adjusts Price Target to $9.20 From $12 - MarketScreener
Wealth Enhancement Advisory Services LLC Takes $347,000 Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Scotiabank Downgrades Sage Therapeutics (SAGE) - MSN
Sage Therapeutics (NASDAQ:SAGE) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of “Hold” from Analysts - Defense World
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: CARM, GNTY, TSBX, and SAGE - Eastern Progress
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
What Makes Sage Therapeutics (SAGE) a New Buy Stock - Yahoo Finance
Sage to lay off most staff amid Supernus buyout - BioPharma Dive
Levi & Korsinsky Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 – SAGE - ACCESS Newswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Phathom Pharmaceuticals Strengthens Leadership: Sage Therapeutics Legal Head Joins GI-focused Biotech as CLO - Stock Titan
SAGE: Baird Adjusts Price Target on Sage Therapeutics | SAGE Stock News - GuruFocus
Canaccord Genuity Group Issues Positive Forecast for Sage Therapeutics (NASDAQ:SAGE) Stock Price - MarketBeat
Needham & Company LLC Reiterates "Hold" Rating for Sage Therapeutics (NASDAQ:SAGE) - MarketBeat
Sage Therapeutics Inc (SAGE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.32%
1.57%
자본화:
|
볼륨(24시간):